The University of Southampton
University of Southampton Institutional Repository

What's new in the management of cutaneous T-cell lymphoma

What's new in the management of cutaneous T-cell lymphoma
What's new in the management of cutaneous T-cell lymphoma
The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.
cutaneous lymphoma, electron beam therapy, novel therapies, radiotherapy
0936-6555
174-184
McFarlane, V.
4e5f8c6e-eb39-4fc6-adfd-46626f073a26
Friedmann, P.S.
d50bac23-f3ec-4493-8fa0-fa126cbeba88
Illidge, T.M.
43b02dd8-7761-4781-b10b-877e26222508
McFarlane, V.
4e5f8c6e-eb39-4fc6-adfd-46626f073a26
Friedmann, P.S.
d50bac23-f3ec-4493-8fa0-fa126cbeba88
Illidge, T.M.
43b02dd8-7761-4781-b10b-877e26222508

McFarlane, V., Friedmann, P.S. and Illidge, T.M. (2005) What's new in the management of cutaneous T-cell lymphoma. Clinical Oncology, 17 (3), 174-184. (doi:10.1016/j.clon.2004.11.010).

Record type: Article

Abstract

The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.

This record has no associated files available for download.

More information

Published date: 2005
Keywords: cutaneous lymphoma, electron beam therapy, novel therapies, radiotherapy

Identifiers

Local EPrints ID: 27267
URI: http://eprints.soton.ac.uk/id/eprint/27267
ISSN: 0936-6555
PURE UUID: 514acf59-9757-4a6b-828d-d384edce8e24

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Mar 2024 07:17

Export record

Altmetrics

Contributors

Author: V. McFarlane
Author: P.S. Friedmann
Author: T.M. Illidge

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×